Bausch + Lomb (BLCO) to Release Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, October 30th. Analysts expect Bausch + Lomb to post earnings of $0.16 per share for the quarter. Bausch + Lomb has set its FY 2024 guidance at EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.13 EPS for the quarter, hitting analysts’ consensus estimates of $0.13. The firm had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.17 billion. Bausch + Lomb had a negative net margin of 10.15% and a positive return on equity of 3.36%. The business’s revenue for the quarter was up 17.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.18 EPS. On average, analysts expect Bausch + Lomb to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Bausch + Lomb Price Performance

Shares of NYSE:BLCO opened at $20.37 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.65 and a quick ratio of 1.01. Bausch + Lomb has a one year low of $13.16 and a one year high of $21.69. The company’s fifty day moving average price is $18.26 and its 200-day moving average price is $16.31. The firm has a market capitalization of $7.17 billion, a price-to-earnings ratio of -21.22, a PEG ratio of 1.76 and a beta of 0.48.

Insider Transactions at Bausch + Lomb

In related news, CEO Brent L. Saunders bought 32,250 shares of the company’s stock in a transaction dated Monday, August 5th. The stock was purchased at an average cost of $15.66 per share, with a total value of $505,035.00. Following the transaction, the chief executive officer now owns 595,169 shares in the company, valued at approximately $9,320,346.54. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.15% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on BLCO shares. Deutsche Bank Aktiengesellschaft increased their target price on shares of Bausch + Lomb from $14.00 to $18.00 and gave the company a “hold” rating in a report on Thursday, August 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a report on Monday, September 16th. HC Wainwright increased their target price on shares of Bausch + Lomb from $19.00 to $22.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Raymond James initiated coverage on shares of Bausch + Lomb in a report on Wednesday, July 10th. They set an “outperform” rating and a $19.00 target price on the stock. Finally, Evercore raised their price target on shares of Bausch + Lomb from $15.50 to $17.00 and gave the stock an “in-line” rating in a report on Thursday, August 1st. Five research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.27.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.